Anumana earns first full FDA clearance for AI to detect low ejection fraction
Related Articles
Pfizer and Anumana Ink Multi-Year AI Electrocardiogram Algorithm Deal
FDA News: Pfizer has entered into a multi-year deal with Anumana — a joint venture between the Mayo Clinic and nference, an electronic health record data company — to develop…{post_date: F d, Y}
Anumana’s AI tool for pulmonary hypertension gets FDA breakthrough status
Medical Device Network: Anumana has received US Food and Drug Administration (FDA) Breakthrough Device Designation for its artificial intelligence (AI)-enhanced, electrocardiogram (ECG)-based Pulmonary Hypertension (PH) Early Detection Algorithm. The accurate,…{post_date: F d, Y}
Novartis turns to algorithms developer Anumana to apply AI to cardio conditions
Med City News: Novartis is partnering with algorithms startup Anumana to develop a new artificial intelligence-based solution for cardiovascular diseases. The goal is to find ways to detect heart conditions…{post_date: F d, Y}
Pfizer to partner with Mayo Clinic spinoff on early cardiac amyloidosis detection
Medtech Dive: Anumana, a health technology startup spun out of Mayo Clinic, entered a multi-year agreement with Pfizer to develop an algorithm to detect cardiac amyloidosis, a serious heart condition.…{post_date: F d, Y}